My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Thursday after the company announced a collaboration with the ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

We recently published a list of 10 Stocks Kick Off Trading Week With Losses. In this article, we are going to take a look at ...

Baidu, Inc. (NASDAQ:BIDU) retreated on Tuesday, losing 7.51 percent to close at $90.16 apiece as investors unloaded ...

Tempus AI (TEM) announced a new collaboration with the Institute for Follicular Lymphoma Innovation. The collaboration aims to develop and make ...

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...